Coimmune Inc. has obtained a license to target delta-like ligand 3 (DLL3) with IL-18 armored chimeric antigen receptor (CAR) technology. The company exercised an option to obtain an exclusive license in the DLL3-targeted, allogeneic CAR-cytokine induced killer (CAR-CIK) cell therapy field to IL-18 armored CAR technology under an agreement with Memorial Sloan Kettering Cancer Center (MSK).
Coimmune Inc. has exercised its option to obtain an exclusive license to IL-18 armored chimeric antigen receptor (CAR) technology under a prior agreement with Memorial Sloan Kettering Cancer Center (MSK). The company plans to couple the technology with allogeneic cytokine induced killer (CIK) cells to launch the clinical development of CMN-008 (armored CAR-CIK cells), with CD19 as the initial target in B-cell malignancies.
Findings published in Nature showing that dual blockage of PD-L1 and CD47 can boost the therapeutic effects of oxaliplatin chemotherapy as well as the FOLFOX regimen – in a CT-26 mice tumor model, anyway – served to highlight CD47, a target that has spurred added efforts of late.
It’s been a rapid year of change for Coimmune Inc., which was incorporated only 12 months ago and now has FDA approval of an IND clearing the way for a phase IIb trial using CMN-001 to treat advanced metastatic renal cell carcinoma (mRCC).
